The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $207,262 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Washington University in St. Louis to develop an mRNA vaccine against Bourbon virus, an emerging tick-borne pathogen. The primary objectives are to evaluate the vaccine's efficacy in a mouse model and determine its mechanism of action. A secondary objective is to test different viral antigens and combinations to assess heterologous protection against other Thogotoviruses, with the goal of developing a pan-pathogen mRNA vaccine. Successful completion of this 2-year research project will provide preliminary data to support a future R01 application for a universal tick-borne disease vaccine. The Washington University Office of Sponsored Research Services, a prominent research division within the private university, will lead this federally funded research effort.
Generated 3/18/25, 5:03 AM